Efficient delivery of angiostatin K1-5 into tumors following insertion of an NGR peptide into adenovirus capsid

Gene Therapy

Volumn 16, Issue 12, 2009, Pages 1405-1415

  Jullienne, B ^a,b   Vigant, F ^a,b   Muth, E ^a,b   Chaligne R ^b   Bouquet, C ^a,c   Giraudier, S ^b   Perricaudet, M ^a,b   Benihoud, K ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Bioalliance   (France)

Author keywords

Adenovirus; Aminopeptidase N; Angiostatin; Capsid engineering; Integrin

Indexed keywords

ADENOVIRUS VECTOR; ANGIOSTATIN; ARGININE; ASPARAGINE; BETA GALACTOSIDASE; CAPSID PROTEIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GLYCINE; MICROSOMAL AMINOPEPTIDASE; VITRONECTIN RECEPTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC GENE THERAPY; ARTICLE; BIOCHEMISTRY; BREAST CARCINOMA; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FIBROSARCOMA; GENE INSERTION; GENETIC ANALYSIS; GENETIC TRANSDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; PSEUDOTYPING; RECEPTOR BINDING; RHABDOMYOSARCOMA; TUMOR CELL; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

ADENOVIRIDAE; ANGIOSTATINS; ANIMALS; ANTIGENS, CD13; CAPSID; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CYTOKINE RECEPTOR GP130; ENDOTHELIAL CELLS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MICE; NEOPLASMS; OLIGOPEPTIDES; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; MIRIDAE;

EID: 73849115332     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.97     Document Type: Article

References (48)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
2. Rafii S, Lyden D. Cancer. A few to flip the angiogenic switch. Science (New York, NY) 2008; 319: 163-164.
3. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286. (Pubitemid 46505878)
4. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angio-genesis. Cancer res 2005; 65: 3967-3979.
5. Soff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000; 19: 97-107.
6. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
7. Galaup A, Magnon C, Rouffiac V, Opolon P, Opolon D, Lassau N et al. Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice. Gene therapy 2005; 12: 831-842.
8. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp cell res 2006; 312: 594-607.
9. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998; 95: 6367-6372.
10. Wen XY, Bai Y, Stewart AK. Adenovirus-mediated human endostatin gene delivery demonstrates strain-specific antitumor activity and acute dose-dependent toxicity in mice. Hum Gene Ther 2001; 12: 347-358.
11. Mahasreshti PJ, Kataram M, Wang MH, Stockard CR, Grizzle WE, Carey D et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 2003; 9: 2701-2710.
12. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-485.
13. Coyne CB, Bergelson JM. CAR: a virus receptor within the tight junction. Adv Drug Deliv Rev 2005; 57: 869-882.
14. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2004; 6(Suppl 1): S152-S163.
15. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer res 1999; 59: 325-330.
16. Pearson AS, Koch PE, Atkinson N, Xiong M, Finberg RW, Roth JA et al. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res 1999; 5: 4208-4213.
17. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer res 1998; 58: 5738-5748.
18. Cripe TP, Dunphy EJ, Holub AD, Saini A, Vasi NH, Mahller YY et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyo-sarcoma cells. Cancer res 2001; 61: 2953-2960.
19. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer res 2000; 60: 5031-5036.
20. Okegawa T, Pong RC, Li Y, Bergelson JM, Sagalowsky AI, Hsieh JT. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer res 2001; 61: 6592-6600.
21. Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adenoviruses \-selective retargeting to tumor cells. Oncogene 2005; 24: 7775-7791.
22. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
23. Hemminki A, Belousova N, Zinn KR, Liu B, Wang M, Chaudhuri TR et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001; 4: 223-231.
24. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Therapy 2001; 8: 730-735.
25. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002; 5: 695-704.
26. Koizumi N, Mizuguchi H, Utoguchi N, Watanabe Y, Hayakawa T. Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. J Gene Med 2003; 5: 267-276.
27. Nakamura T, Sato K, Hamada H. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Hum Gene Ther 2002; 13: 613-626.
28. Wickham TJ, Tzeng E, Shears 2nd LL, Roelvink PW, Li Y, Lee GM et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229.
29. Wu H, Han T, Lam JT, Leath CA, Dmitriev I, Kashentseva E et al. Preclinical evaluation of a class of infectivity-enhanced adeno-viral vectors in ovarian cancer gene therapy. Gene Therapy 2004; 11: 874-878.
30. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (New York, NY) 1998; 279: 377-380.
31. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002; 62: 867-874.
32. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol 1994; 124: 373-380.
33. Koivunen E, Arap W, Rajotte D, Lahdenranta J, Pasqualini R. Identification of receptor ligands with phage display peptide libraries. J Nucl Med 1999; 40: 883-888.
34. Shim JS, Kim JH, Cho HY, Yum YN, Kim SH, Park HJ et al. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol 2003; 10: 695-704.
35. Reaux A, Fournie-Zaluski MC, David C, Zini S, Roques BP, Corvol P et al. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci USA 1999; 96: 13415-13420.
36. Vigant F, Descamps D, Jullienne B, Esselin S, Connault E, Opolon P et al. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 2008; 16: 1474-1480.
37. Sirena D, Lilienfeld B, Eisenhut M, Kalin S, Boucke K, Beerli RR et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 2004; 78: 4454-4462.
38. Majhen D, Gabrilovac J, Eloit M, Richardson J, Ambriovic-Ristov A. Disulfide bond formation in NGR fiber-modified adenovirus is essential for retargeting to aminopeptidase N. Biochem Biophys Res Commun 2006; 348: 278-287.
39. Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood 2008; 112: 2628-2635.
40. Pasqualini R, Arap W, McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 2002; 8: 563-571.
41. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 2000; 268: 382-390.
42. Vigne E, Mahfouz I, Dedieu JF, Brie A, Perricaudet M, Yeh P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 1999; 73: 5156-5161.
43. Martin K, Brie A, Saulnier P, Perricaudet M, Yeh P, Vigne E. Simultaneous CAR-and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol Ther 2003; 8: 485-494.
44. Von Seggern DJ, Huang S, Fleck SK, Stevenson SC, Nemerow GR. Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J Virol 2000; 74: 354-362.
45. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (New York, NY) 1996; 272: 263-267.
46. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (New York, NY) 1997; 275: 1320-1323.
47. Liszewski MK, Tedja I, Atkinson JP. Membrane cofactor protein (CD46) of complement. Processing differences related to alternatively spliced cytoplasmic domains. J Biol Chem 1994; 269: 10776-10779.
48. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 1983; 80: 3734-3737.